Cowen’s healthcare analyst Boris Peaker weighed in today with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), following yesterday’s meeting with the company’s management team. The …
Cowen analyst Boris Peaker was out today with a research note on Keryx Biopharma (NASDAQ:KERX), following Friday’s release of IMS scripts data for Aurixya. The analyst rates …
Cowen analyst Boris Peaker weighed in today with his thoughts on Keryx Biopharmaceuticals (NASDAQ:KERX), following the news that the FDA approved Rockwell Medical’s (NASDAQ:RMTI) Triferic …
In a research report issued this morning, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 …
J.P.
In a research report issued today, MLV analyst George Zavoico maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and raised his price target …
In a research report released today, H.C.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharma (NASDAQ:KERX) and raised his price …
